Abstract: The present application provides chimeric antigen receptors (CARs) comprising an anchoring domain, such as a PDZ binding motif, which binds to a cell polarity protein. Also provided are poly nucleotides encoding the CARs, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

Abstract: The present disclosure relates generally to methods for generating a pre-effector gene signature for determining the C cytotoxic effector potential of a preparation of chimeric antigen receptor (CAR) T cells comprising measuring single-cell gene expression data and endogenous T cell receptor (TCR) sequencing data of the preparation of CAR T cells. The present invention relates also to methods for determining the cytotoxic effector potential of a preparation of CAR T cells or a subset of CAR T cells therefrom as well as methods for treating a cancer in a subject in need thereof by administering a preparation of CAR T cells determined to have a cytotoxic effector potential.

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and IL10 signaling pathway is enhanced. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

Abstract: The application provides chimeric antigen receptors (CARs) that target splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (Col11A1), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the chimeric antigen receptors, as well as host cells comprising the chimeric antigen receptors. The application also provides methods for preparing host cells comprising the chimeric antigen receptors and methods for treating patients using the modified host cells.

Abstract: The present invention provides methods of genetically modifying an immune cell such that the immune cell expresses a transgene in an activation dependent manner. The application also provides genetically modified immune cells prepared using such methods, and the uses of the genetically modified immune cells in immunotherapy (e.g., adoptive cell therapy) for treatment of a disease such as cancer, autoimmune disease or infectious disease.

Abstract: The present disclosure provides chimeric MyD88 receptors. Also provided are polynucleotides encoding the chimeric MyD88 receptors, vectors comprising the polynucleotides encoding the chimeric MyD88 receptors, and cell compositions comprising the chimeric MyD88 receptors, polynucleotides and/or vectors. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.

Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising a B7-H3 binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the isolated host cells and methods for treating a tumor using the pharmaceutical compositions.

Abstract: The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.

Abstract: Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.

Abstract: The application provides T cell gene expression signatures that can be used to predict T cell therapy outcomes.

Abstract: The application relates to a chimeric antigen receptor that directly and/or indirectly targets cells and their uses in tumor immunotherapy. The application also relates to polynucleotides that encode the chimeric antigen receptor and optionally accessory genes, vectors, and host cells comprising the chimeric antigen receptor and optionally a second antigen targeting moiety (e.g., a second chimeric antigen receptor or a bispecific molecule). The application also relates to methods for preparing host cells comprising the chimeric antigen receptor and optionally the second antigen targeting moiety.

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

Abstract: An electromagnetic machine includes a housing, an axle coupled to the housing in a rotatable fashion, a stator assembly disposed generally within the housing, the stator assembly including a stator plate and a stator bearing coupled to the axle such that the stator assembly is rotatable about the axle, a rotor assembly fixed to the axle and disposed generally within the housing and including a rotor housing that defines a circumferentially extending channel that is sized to receive a portion of the stator assembly therein; and a locking mechanism configured to selectively prevent and permit rotation of the stator assembly about the axle via the stator bearing. The housing can include an access window defined therein such that the stator assembly is accessible through the access window.

Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have enhanced antitumor properties and/or can be regulated by safety switches. Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a cancer in a subject are also provided.

Abstract: An electromagnetic machine includes a housing, an axle coupled to the housing in a rotatable fashion, a stator assembly disposed generally within the housing, the stator assembly including a stator plate and a stator bearing coupled to the axle such that the stator assembly is rotatable about the axle, a rotor assembly fixed to the axle and disposed generally within the housing and including a rotor housing that defines a circumferentially extending channel that is sized to receive a portion of the stator assembly therein; and a locking mechanism configured to selectively prevent and permit rotation of the stator assembly about the axle via the stator bearing. The housing can include an access window defined therein such that the stator assembly is accessible through the access window.

Abstract: The application relates to a chimeric antigen receptor that targets Eph receptors and allows activation of co-stimulatory pathways. The application also relates to polynucleotides that encode the chimeric antigen receptor, vectors, and host cells comprising the chimeric antigen receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo effector function of the chimeric antigen receptor host cells.

Abstract: An electromagnetic machine includes a housing, an axle coupled to the housing in a rotatable fashion, a stator assembly disposed generally within the housing, the stator assembly including a stator plate and a stator bearing coupled to the axle such that the stator assembly is rotatable about the axle, a rotor assembly fixed to the axle and disposed generally within the housing and including a rotor housing that defines a circumferentially extending channel that is sized to receive a portion of the stator assembly therein; and a locking mechanism configured to selectively prevent and permit rotation of the stator assembly about the axle via the stator bearing. The housing can include an access window defined therein such that the stator assembly is accessible through the access window.

Abstract: Provided here are compositions comprising engineered lymphocytes that secrete bispecific engager molecules, thereby activating T cells in the local environment to kill target cells. In particular embodiments, engineered lymphocytes selectively target CLL-1 positive leukemic cells, both directly and through activation of a subject's own T cells, while sparing CLL-1 negative cells, such as myeloid progenitor cells. In particular embodiments, engineered lymphocytes selectively target CD123 and CLL-1 positive leukemic cells, both directly and through activation of native T cells.